GLP-1s and Kidney Health: Benefit, Risk, and What to Track

Benefit evidence and safety risk can both be true

Part 1 · outcome evidence

A product- and population-specific benefit

The labelled kidney indication applies to Ozempic in adults with type 2 diabetes and chronic kidney disease. [1] It does not establish that every GLP-1 protects every person.

Part 2 · safety warning

Volume depletion can create kidney risk

The Ozempic label warns about acute kidney injury due to volume depletion. Most postmarketing reports occurred after nausea, vomiting, diarrhea, or other gastrointestinal reactions led to dehydration. [1]

What FLOW actually found

FLOW randomized 3,533 participants with type 2 diabetes and chronic kidney disease and followed them for a median of 3.4 years. Semaglutide lowered the relative risk of the primary composite outcome by 24% compared with placebo: 331 first events versus 410, with a hazard ratio of 0.76 (95% confidence interval, 0.66–0.88). [2]

The composite included kidney failure, a sustained eGFR decline of at least 50%, or death from kidney or cardiovascular causes. [2]

New, October 2026: GLP-1 drugs in people on hemodialysis

The question: FLOW excluded people already on dialysis, so what happens in that group? The short answer: a new US records study links semaglutide with somewhat fewer deaths and hospital stays than dulaglutide and liraglutide combined, in people with diabetes on maintenance hemodialysis; against liraglutide alone the difference was not statistically significant. It is observational, not a randomized trial. [4]

The study, published online ahead of print on October 27, 2026 in Diabetes Care by Le, Shin and colleagues at Thomas Jefferson University, Johns Hopkins, NYU and others, used 2011–2022 U.S. Renal Data System and Medicare data to emulate a “target trial,” comparing 1,312 people who started semaglutide with 2,601 who started dulaglutide or liraglutide, with statistical weighting to balance the groups. Median follow-up was 1.1 years. [4]

Death on dialysis: 1-year cumulative incidence 11% with semaglutide versus 13% (subdistribution hazard ratio 0.82, 95% CI 0.70–0.97). [4]
Any hospitalization: 57% versus 62% at 1 year (sHR 0.91, 0.83–0.99). [4]
Body weight at 1 year: −4.8% versus −3.4%. [4]
By comparator: results were similar against dulaglutide alone, but against liraglutide alone the abstract reports no statistically significant benefit for death or hospitalization. [4]

The authors conclude: “Among patients with diabetes receiving hemodialysis and equipoise between semaglutide and dulaglutide or liraglutide, semaglutide may be the preferred glucagon-like peptide 1 agent compared with dulaglutide.” [4]

Limits. Observational data can be confounded by who gets which drug, even after weighting; follow-up was about a year; and the abstract does not compare GLP-1 drugs with no GLP-1 drug. We read the abstract only through PubMed and could not check full methods, funding or disclosures. [4] FLOW, the randomized kidney trial above, excluded people on dialysis or who had been on it in the previous 90 days. [2][5]

Our analysis: this is a hypothesis-strengthening signal for one specific, high-risk group, not proof that one drug causes better survival. Choosing or switching a medicine on dialysis belongs with the nephrology and diabetes team.

Two kidney measurements, two complementary views

NIDDK says providers use a blood test for GFR or eGFR and a urine albumin test or UACR to diagnose and monitor kidney disease. [3] These measurements describe different parts of the story; they are not a diagnosis generated by a tracker.

Blood

eGFR: filtration

A blood test is used to estimate GFR, which NIDDK describes as a check of how well the kidneys filter blood. [3]

Urine

UACR: albumin leakage

A urine albumin test checks for albumin in urine. NIDDK notes that an abnormal urine albumin result may be repeated to confirm it; what a result means belongs with the clinician. [3]

A neutral tracking framework

The useful record keeps events in sequence without trying to interpret them:

1. Copy each lab exactly. Record the lab name, value, units, reference range, date, and source.
2. Name the product. Record the exact medication or product name and any clinician-directed changes.
3. Time-stamp GI symptoms. Note nausea, vomiting, or diarrhea and whether fluids could be kept down.
4. Preserve sequence. Keep symptoms and labs in date order without assigning cause.
5. Carry questions forward. Bring unresolved questions to the prescriber.

What not to infer

The kidney benefit in FLOW does not erase the label’s kidney safety warning.

A symptom log cannot prove acute kidney injury.

One lab point does not establish why it changed.

A tracker cannot screen interactions or treatment suitability.

Questions for the prescriber

Which kidney measurements matter for my condition and product?
What change would you want reported?
If gastrointestinal symptoms occur, what is the plan for contacting the office and labs?
How should I record clinician-directed medication changes?

Frequently asked questions

Does Ozempic protect the kidneys?

The current Ozempic label includes reducing the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. In FLOW, semaglutide reduced the relative risk of the primary composite outcome by 24% versus placebo in that specific studied population. This is not a universal claim for every GLP-1 or every person. [1] [2]

Can semaglutide affect kidney safety?

Yes. The current Ozempic label warns about acute kidney injury due to volume depletion. Most postmarketing reports occurred after gastrointestinal reactions leading to dehydration, including nausea, vomiting, or diarrhea. [1]

Which kidney tests tell different parts of the story?

NIDDK describes eGFR, based on a blood test, as a view of kidney filtration and UACR, based on a urine albumin test, as a view of albumin leakage. They are complementary measurements, not a diagnosis from a tracker. [3]

Can Jabbit interpret kidney labs?

No. Jabbit keeps clinician-directed injection schedules, reminders, injection history, progress, and symptom timing together. It does not interpret labs, diagnose kidney problems, or choose treatment.

Sources opened and checked

Sources 1–3 were opened and checked on July 24, 2026; source 4 (abstract only) on October 31, 2026; source 5 on November 2, 2026.

GLP-1 bloodwork monitoring Build a prescriber-ready protocol history GLP-1 injection tracking